Solid-state forms of zoledronic acid: Polymorphism in hydrates

Journal of Pharmaceutical Sciences

Volumn 99, Issue 12, 2010, Pages 4962-4972

  Ruscica, Romina ^a   Bianchi, Micaela ^a   Quintero, Mariano ^a,b   Martinez, Andrea ^c   Vega, Daniel R ^a,b  

^a DEPARTAMENTO DE FÍSICA   (Argentina)

^b UNIVERSIDAD NACIONAL DE SAN MARTÍN   (Argentina)

^c Gador SA   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

NITROGEN; ZOLEDRONIC ACID;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG STRUCTURE; HUMIDITY; HYDRATION; THERMOGRAVIMETRY; ULTRAVIOLET SPECTROPHOTOMETRY; X RAY DIFFRACTION;

EID: 78049512487     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22223     Document Type: Article

References (32)

1. Rogers MJ. 2003. New insights into the molecular mechanism of action of bisphosphonates. Curr Pharm Des 9: 2643-2658.
2. Masarachia P, Weinreb M, Balena R, Roldan GA. 1996. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 19: 281-290.
3. Cremers SCLM, Pillai G, Papapoulos SE. 2005. Pharmacokinetics/pharmacodynamics of bisphosphonates. Clin Pharmacokinet 44: 551-570.
4. Papapoulos SE. 2006. Bisphosphonate actions: Physical chemistry revisited. Bone 38: 613-616.
5. Russell RGG. 2006. Bisphosphonates: From bench to bedside. Ann NY Acad Sci 1068: 367-401.
6. Russell RGG. 2007. Bisphosphonates: Mode of action and pharmacology. Pediatrics 119: S150-S162.
7. Van Beek E, Cohen L, Leroy I, Ebetino F, Löwik C, Papapoulos S. 2003. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 33: 805-811.
8. Kimmel DB. 2007. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 86: 1022-1033.
9. Reid IR. 2002. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346: 653-661.
10. Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S. 2007. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357: 1799-1809.
11. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR. 2007. Once-yearly Zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356: 1809-1822.
12. Chemburkar SR, Bauer J, Deming K, Spiwek H, Patel K, Morris J, Henry R, Spanton S, Dziki W, Porter W, Bauer P, Donaubauer J, Narayanan BA, Soldani M, Riley D, McFarland K. 2000. Dealing with the impact of Ritonavir polymorphs on the late stages of bulk drug process development. Org Proc Res Dev 4: 413-417.
13. Newman AW, Byrn SR. 2003. Solid state analysis of active ingredient in drug products. Drug Disc Today 8: 898-905.
14. Sanders JM, Ortiz Gómez A, Mao J, Meints GA, Van Brussel EM, Burzynska A, Kafarski P, González-Pacanowska D, Oldfield E. 2003. 3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates. J Med Chem 46: 5171-5183.
15. Wikstrom H, Marsac PJ, Taylor LS. 2005. In-line monitoring of hydrate formation during wet granulation using Raman spectroscopy. J Pharm Sci 94: 209-219.
16. Williams AC, Cooper VB, Thomas L, Griffith LJ, Petts CR, Booth SW. 2004. Evaluation of drug physical form during granulation, tabletting and storage. Int J Pharm 275: 29-39.
17. Gift AD, Luner PE, Luedeman L, Taylor LS. 2009. Manipulating hydrates formation during high shear wet granulation using polymeric excipients. J Pharm Sci 98: 4670-4683.
18. Petrova RI, Peresypkin A, Mortko CJ, Mckeown AE, Lee J, Williams JM. 2009. Rapid convertion of API hydrates to anhydrous forms in aqueous media. J Pharm Sci 98: 4111-4118.
19. Phadnis NV, Suryanarayanan R. 1997. Polymorphism in anhydrous theophylline-Implications on the dissolution rate of theophylline tablets. J Pharm Sci 84: 318-323.
20. Dugue J, Ceolin R, Rouland JC, Lepage F. 1991. Polymorphism of carbamazepine: Solid-state studies on carbamazepine dihydrate. Pharm Acta Helv 66: 307-310.
21. Saleki-Herhardt A, Stowell JG, Byrn SR, Zografi G. 1995. Hydration and dehydration of crystalline and amorphous forms of raffinose. J Pharm Sci 84: 318-323.
22. Li YH, Han J, Zhang GGZ, Grant DJW, Suryanarayanan R. 2000. In situ dehydration of carbamazepine dihydrate: A novel technique to prepare amorphous carbamazepine. Pharm Dev Tech 5: 257-266.
23. Sheldrick GM. 1997. SHELXS97 and SHELXL97. Germany: University of Göttingen.
24. Farrugia LJ. 1999. WinGX. J Appl Cryst 32: 837-838.
25. Allen FH. 2002. The Cambridge Structural Database: A quarter of a million crystal structures and rising. Acta Cryst B58: 380-388.
26. Vega DR, Fernández D, Ellena JA. 2002. Disodium pamidronate. Acta Cryst C58: m77-m80.
27. Fernández D, Vega DR. 2003. Head-to-head dimers in the zwitterion of 1-hydroxy-3-(pyrrolidin-1-yl) propylidene-1, 1-bisphosphonic acid (EB 1053). Acta Cryst C59: o228-o230.
28. Leroux Y, Manouni E, Safsaf D, Neuman A, Giller H. 1991. Etude structurale de ĺacide butane hydroxy-1-amino-4 diphosphonique-1, 1. Phosphorous Sulfur Silicon Relat Elem 63: 181-191.
29. Vega D, Baggio R, Garland MT. 1996. Monosodium 4-amino-1-hydroxy-1, 1-butanediyldiphosphonate trihydrate (alendronate). Acta Cryst C52: 2198-2201.
30. Verna AR, Krishna P. 1966. Polymorphism and polytypism in crystals. John Wiley. New York: pp. 15-30.
31. Fetch HJ. 1992. Defect-induced melting and solid state amorphization. Nature 356: 133-135.
32. Bates S, Kelly RC, Ivanisevic I, Shields P, Zografi G, Newman AW. 2007. Assessment of defects and amorphous structure produced in Raffinose pentahydrate upon dehyration. J Pharm Sci 96: 1418-1433.